What You Should Know:
– Cellbyte, the AI-native platform that helps pharmaceutical companies accelerate drug launches, announces that it has raised $2.75 million in seed funding.
– The round was led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital and Springboard Health Angels.
Cellbyte: Rebuilding Global Drug Launch Workflows for the AI Era
Cellbyte is an AI-native platform transforming how pharmaceutical companies prepare, price, and launch new drugs worldwide. By automating data extraction and insight generation across complex regulatory and market access workflows, it enables faster, more precise decision-making at global scale. Backed by leading investors, Cellbyte is trusted by major pharmaceutical brands and is rapidly expanding its footprint across the U.S. and Europe.
Pharmaceutical launch teams confront a notoriously fragmented data ecosystem. Regulatory submissions, pricing analyses, reimbursement dossiers, and market access documentation require thousands of inputs pulled from inconsistent, manually compiled sources. As a result, life-saving therapies can take more than a year to reach the patients who need them most. Companies often spend hundreds of thousands of dollars buying siloed datasets or contracting external consultants simply to navigate foundational information.
Cellbyte approaches this problem with a fully AI-native architecture that brings clinical, pricing, HTA, regulatory, and internal company data into a unified, real-time analytical environment. Teams can evaluate millions of data points instantly, enabling rapid dossier preparation, scenario modeling, launch sequence mapping, and go-to-market strategy development—compressing entire workflows from months to minutes without compromising precision or quality.
Traditional databases were constructed before the LLM revolution and only surface top-layer information. Cellbyte delivers deeper, continuously updated, interconnected datasets tied directly to the operational needs of pricing and market access teams. This next-generation foundation streamlines the most time-sensitive and high-stakes components of global drug launches, allowing companies to move significantly faster with greater confidence in their decisions.
Felix Steinbrenner, Co-CEO and Co-Founder, notes that the trajectory of a drug’s entire commercial lifecycle is shaped by its launch sequence. He emphasizes that high-fidelity insights extracted from gigabytes of up-to-date data are essential for optimizing this process—an area where Cellbyte’s rapid traction among major global pharmaceutical companies underscores a readiness to adopt higher-quality, more efficient workflows.
Founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, Cellbyte combines expertise across pharmaceutical consulting, AI/ML engineering, and company building. Daniel contributes firsthand insight into the legacy data practices that slow drug launches; Samuel brings deep technical experience in developing AI systems; and Felix adds operational leadership as a repeat founder and Y Combinator alumnus.
Cellbyte has grown rapidly since launch, surpassing six-figure ARR within weeks, expanding into major global markets, and securing enterprise contracts with brands such as Bayer. With new investment, the company will triple its headcount and scale its engineering capabilities to meet rising demand. This growth strategy positions Cellbyte to become the operating system of choice for commercial pharmaceutical teams aiming to accelerate and modernize global drug launches.
